Anavex Life Sciences Corp. (0HFR.L)

USD 9.08

(-3.55%)

Long Term Debt Summary of Anavex Life Sciences Corp.

  • Anavex Life Sciences Corp.'s latest annual long term debt in 2023 was - USD , down 0.0% from previous year.
  • Anavex Life Sciences Corp.'s latest quarterly long term debt in 2024 Q3 was - USD , down 0.0% from previous quarter.
  • Anavex Life Sciences Corp. reported annual long term debt of - USD in 2022, down 0.0% from previous year.
  • Anavex Life Sciences Corp. reported annual long term debt of - USD in 2021, down 0.0% from previous year.
  • Anavex Life Sciences Corp. reported quarterly long term debt of - USD for 2024 Q1, down 0.0% from previous quarter.
  • Anavex Life Sciences Corp. reported quarterly long term debt of - USD for 2024 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Anavex Life Sciences Corp. (2023 - 2004)

Historical Annual Long Term Debt of Anavex Life Sciences Corp. (2023 - 2004)

Year Long Term Debt Long Term Debt Growth
2023 - USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD -100.0%
2015 332.00 USD -99.99%
2014 5.71 Million USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%
2004 - USD 0.0%

Peer Long Term Debt Comparison of Anavex Life Sciences Corp.

Name Long Term Debt Long Term Debt Difference
Editas Medicine, Inc. 24.37 Million USD 100.0%
Dynavax Technologies Corporation 252.41 Million USD 100.0%
Supernus Pharmaceuticals, Inc. 33.19 Million USD 100.0%
Perrigo Company plc 3.63 Billion USD 100.0%
Illumina, Inc. 1.48 Billion USD 100.0%
Thermo Fisher Scientific Inc. 31.3 Billion USD 100.0%
Iovance Biotherapeutics, Inc. 1 Million USD 100.0%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 100.0%
IQVIA Holdings Inc. 12.95 Billion USD 100.0%
Heron Therapeutics, Inc. 173.75 Million USD 100.0%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 100.0%
Unity Biotechnology, Inc. 23.53 Million USD 100.0%
Waters Corporation 2.3 Billion USD 100.0%
Biogen Inc. 7.18 Billion USD 100.0%
Sangamo Therapeutics, Inc. 33.51 Million USD 100.0%
Evolus, Inc. 120.35 Million USD 100.0%
Adicet Bio, Inc. 17.7 Million USD 100.0%
Cara Therapeutics, Inc. 37.07 Million USD 100.0%
bluebird bio, Inc. 224.41 Million USD 100.0%
Esperion Therapeutics, Inc. 501.54 Million USD 100.0%
FibroGen, Inc. 89.69 Million USD 100.0%
Agilent Technologies, Inc. 2.73 Billion USD 100.0%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD 100.0%
Homology Medicines, Inc. 43.17 Million USD 100.0%
Geron Corporation 35.05 Million USD 100.0%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 100.0%
Amicus Therapeutics, Inc. 387.85 Million USD 100.0%
Myriad Genetics, Inc. 130.9 Million USD 100.0%
Viking Therapeutics, Inc. 936 Thousand USD 100.0%
Intellia Therapeutics, Inc. 96.74 Million USD 100.0%
Zoetis Inc. 6.56 Billion USD 100.0%
Abeona Therapeutics Inc. 4.4 Million USD 100.0%
Mettler-Toledo International Inc. 1.97 Billion USD 100.0%
BioMarin Pharmaceutical Inc. 593.09 Million USD 100.0%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 100.0%
Kala Pharmaceuticals, Inc. 34.19 Million USD 100.0%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 100.0%
Atara Biotherapeutics, Inc. 45.69 Million USD 100.0%
Verastem, Inc. 40.08 Million USD 100.0%
Nektar Therapeutics 112.62 Million USD 100.0%
Axsome Therapeutics, Inc. 178.07 Million USD 100.0%
Aclaris Therapeutics, Inc. 3.07 Million USD 100.0%
Sarepta Therapeutics, Inc. 1.13 Billion USD 100.0%
OPKO Health, Inc. 222.03 Million USD 100.0%
Exelixis, Inc. 189.94 Million USD 100.0%
Neurocrine Biosciences, Inc. 258.3 Million USD 100.0%
Corcept Therapeutics Incorporated - USD NaN%
uniQure N.V. 130.06 Million USD 100.0%
Imunon, Inc. 1.13 Million USD 100.0%
Blueprint Medicines Corporation 610.96 Million USD 100.0%
Insmed Incorporated 1.19 Billion USD 100.0%
Halozyme Therapeutics, Inc. 1.49 Billion USD 100.0%
Agios Pharmaceuticals, Inc. 56.98 Million USD 100.0%
TG Therapeutics, Inc. 100.11 Million USD 100.0%
Incyte Corporation 29.16 Million USD 100.0%
Emergent BioSolutions Inc. 446.5 Million USD 100.0%